{"id":332338,"date":"2020-12-09T23:00:01","date_gmt":"2020-12-09T22:00:01","guid":{"rendered":"https:\/\/medizinonline.com\/la-prevention-secondaire-par-la-colchicine-reduit-le-risque-cardiovasculaire\/"},"modified":"2020-12-09T23:00:01","modified_gmt":"2020-12-09T22:00:01","slug":"la-prevention-secondaire-par-la-colchicine-reduit-le-risque-cardiovasculaire","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/la-prevention-secondaire-par-la-colchicine-reduit-le-risque-cardiovasculaire\/","title":{"rendered":"La pr\u00e9vention secondaire par la colchicine r\u00e9duit le risque cardiovasculaire"},"content":{"rendered":"<p><strong>La colchicine est utilis\u00e9e depuis longtemps en m\u00e9decine comme alcalo\u00efde et pr\u00e9sente une large activit\u00e9 anti-inflammatoire. Les r\u00e9sultats d&#8217;\u00e9tudes r\u00e9centes montrent d\u00e9sormais que son utilisation chez les patients atteints de maladie coronarienne stable peut r\u00e9duire de mani\u00e8re significative le risque cardiovasculaire.  <\/strong><\/p>\n<p> <!--more--> <\/p>\n<p>La colchicine, un inhibiteur de mitose pr\u00e9sent dans le colchique d&#8217;automne, r\u00e9duit de pr\u00e8s d&#8217;un tiers, par rapport au placebo, le risque de d\u00e9c\u00e8s d&#8217;origine cardiovasculaire, d&#8217;infarctus du myocarde, d&#8217;accident vasculaire c\u00e9r\u00e9bral ou de revascularisation coronarienne li\u00e9e \u00e0 l&#8217;isch\u00e9mie chez les patients souffrant d&#8217;une maladie coronarienne stable. C&#8217;est la conclusion \u00e0 laquelle sont parvenus des scientifiques en analysant les donn\u00e9es de l&#8217;\u00e9tude LoDoCO2 [1]. Cette vaste \u00e9tude en double aveugle, randomis\u00e9e et contr\u00f4l\u00e9e par placebo a inclus des patients \u00e2g\u00e9s de 35 \u00e0 82 ans pr\u00e9sentant une maladie coronarienne av\u00e9r\u00e9e et stable depuis plus de 6 mois. Au cours de la p\u00e9riode de run-in, tous les patients ont d&#8217;abord \u00e9t\u00e9 trait\u00e9s pendant 30 jours avec 0,5 mg de colchicine par jour. 5522 patients tol\u00e9rant et acceptant la colchicine ont ensuite \u00e9t\u00e9 randomis\u00e9s dans un rapport 1:1 pour recevoir de la colchicine 0,5&nbsp;mg\/jour ou un placebo en plus de leur traitement standard et ont \u00e9t\u00e9 suivis pendant 29 mois en moyenne. Le crit\u00e8re d&#8217;\u00e9valuation principal \u00e9tait le d\u00e9c\u00e8s d&#8217;origine cardiovasculaire, l&#8217;infarctus du myocarde, l&#8217;accident vasculaire c\u00e9r\u00e9bral et la revascularisation coronarienne li\u00e9e \u00e0 l&#8217;isch\u00e9mie. Dans le groupe placebo, 264 patients (9,6%) ont pr\u00e9sent\u00e9 un \u00e9v\u00e9nement du crit\u00e8re d&#8217;\u00e9valuation principal, contre 187 (6,8%) dans le groupe colchicine. En cons\u00e9quence, la colchicine a r\u00e9duit le risque relatif de 31% par rapport au placebo. L&#8217;effet est apparu t\u00f4t et a augment\u00e9 au cours de la p\u00e9riode d&#8217;observation. Les r\u00e9sultats sur les crit\u00e8res d&#8217;\u00e9valuation secondaires sont \u00e9galement en faveur de l&#8217;utilisation de la colchicine.<\/p>\n<p><em>Source : Congr\u00e8s ESC 2020<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>\nLitt\u00e9rature :<\/p>\n<ol>\n<li>Nidorf SM, Fiolet ATL, Mosterd A, et al : Colchicine in Patients with Chronic Coronary Disease. NEJM 2020. DOI : 10.1056\/NEJMoa2021372<\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<p><em>CARDIOVASC 2020 ; 19(3) : 36 (publi\u00e9 le 19.9.20, ahead of print)<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La colchicine est utilis\u00e9e depuis longtemps en m\u00e9decine comme alcalo\u00efde et pr\u00e9sente une large activit\u00e9 anti-inflammatoire. Les r\u00e9sultats d&#8217;\u00e9tudes r\u00e9centes montrent d\u00e9sormais que son utilisation chez les patients atteints de&hellip;<\/p>\n","protected":false},"author":7,"featured_media":99576,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Maladie coronarienne","footnotes":""},"category":[11378,11527,11535,11549],"tags":[],"powerkit_post_featured":[],"class_list":["post-332338","post","type-post","status-publish","format-standard","has-post-thumbnail","category-cardiologie","category-etudes","category-rapports-de-congres","category-rx-fr","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-17 11:01:49","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":332471,"slug":"la-prevenzione-secondaria-con-la-colchicina-riduce-il-rischio-cardiovascolare","post_title":"La prevenzione secondaria con la colchicina riduce il rischio cardiovascolare","href":"https:\/\/medizinonline.com\/it\/la-prevenzione-secondaria-con-la-colchicina-riduce-il-rischio-cardiovascolare\/"},"pt_PT":{"locale":"pt_PT","id":332481,"slug":"a-prevencao-secundaria-com-colchicina-reduz-o-risco-cardiovascular","post_title":"A preven\u00e7\u00e3o secund\u00e1ria com colchicina reduz o risco cardiovascular","href":"https:\/\/medizinonline.com\/pt-pt\/a-prevencao-secundaria-com-colchicina-reduz-o-risco-cardiovascular\/"},"es_ES":{"locale":"es_ES","id":332484,"slug":"la-prevencion-secundaria-con-colchicina-reduce-el-riesgo-cardiovascular","post_title":"La prevenci\u00f3n secundaria con colchicina reduce el riesgo cardiovascular","href":"https:\/\/medizinonline.com\/es\/la-prevencion-secundaria-con-colchicina-reduce-el-riesgo-cardiovascular\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/332338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=332338"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/332338\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/99576"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=332338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=332338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=332338"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=332338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}